STC-004

STC-004 is an oral, highly selective small molecule inhibitor of the voltage-gated sodium channel NaV1.8, developed for the non-opioid treatment of acute and chronic peripheral pain. The drug acts by blocking NaV1.8 channels, which are involved in propagating pain signals from peripheral sensory neurons to the central nervous system. By selectively inhibiting this channel, STC-004 aims to provide effective analgesia without the addictive properties or side effects associated with opioids. In Phase 1 clinical trials, STC-004 demonstrated rapid absorption suitable for once-daily dosing and was well-tolerated at all tested doses with evidence of target engagement and increased pain tolerance threshold in experimental models. SiteOne Therapeutics is advancing development into Phase 2 trials as a potential safer alternative for pain management[1][3][5][7].